Rxivist logo

Rxivist combines biology preprints from bioRxiv and medRxiv with data from Twitter to help you find the papers being discussed in your field. Currently indexing 136,454 papers from 581,733 authors.

Most downloaded biology preprints, all time

in category addiction medicine

61 results found. For more information, click each entry to expand.

1: Comparing rapid micro-induction and standard induction of buprenorphine/naloxone for treatment of opioid use disorder: Protocol for an open-label, parallel-group, superiority, randomized controlled trial
more details view paper

Posted 26 May 2020

Comparing rapid micro-induction and standard induction of buprenorphine/naloxone for treatment of opioid use disorder: Protocol for an open-label, parallel-group, superiority, randomized controlled trial
2,905 downloads medRxiv addiction medicine

James S.H. Wong, Mohammadali Nikoo, Jean N. Westenberg, Janet G. Suen, Jennifer Wong, Reinhard M. Krausz, Christian G. Schutz, Marc Vogel, Jesse A. Sidhu, Jessica Moe, Shane Arishenkoff, Donald Griesdale, Nickie Mathew, Pouya Azar

Background: Buprenorphine/naloxone (Suboxone) is a current first-line treatment for opioid use disorder (OUD). The standard induction method of buprenorphine/naloxone requires patients to be abstinent from opioids and therefore experience withdrawal symptoms prior to induction, which can be a barrier in starting treatment. Rapid micro-induction (micro-dosing) involves the administration of small, frequent does of buprenorphine/naloxone and removes the need for a period of withdrawal prior to the start of treatment. This study aims to compare the effectiveness and safety of rapid micro-induction versus standard induction of buprenorphine/naloxone in patients with OUD. Methods: This is a randomized, open-label, two-arm, superiority, controlled trial comparing the safety and effectiveness of rapid micro-induction versus standard induction of buprenorphine/naloxone for the treatment of OUD. A total of 50 participants with OUD will be randomized at one Canadian hospital. The primary outcome is successful induction of buprenorphine/naloxone with low levels of withdrawal. Secondary outcomes are treatment retention, illicit drug use, self-reported drug use behaviour, craving, pain, physical health, safety, and client satisfaction. Discussion: This is the first randomized controlled trial to compare the effectiveness and safety of rapid micro-induction versus standard induction of buprenorphine/naloxone. This study will thereby generate evidence for a novel induction method which eliminates substantial barriers to the use of buprenorphine/naloxone in the midst of the ongoing opioid crisis.

2: A global survey on changes in the supply, price and use of illicit drugs and alcohol, and related complications during the 2020 COVID-19 pandemic
more details view paper

Posted 21 Jul 2020

A global survey on changes in the supply, price and use of illicit drugs and alcohol, and related complications during the 2020 COVID-19 pandemic
1,303 downloads medRxiv addiction medicine

Ali Farhoudian, Seyed Ramin Radfar, Hossein Mohaddes Ardabili, Parnian Rafei, Mohsen Ebrahimi, Arash Khojasteh Zonoozi, Cornelis A J De Jong, Mehrnoosh Vahidi, Masud Yunesian, Christos Kouimtsidis, Shalini Arunogiri, Helena Hansen, Kathleen T Brady, Marc Potenza, ISAM-PPIG Global Survey Consortium, Alexander Mario Baldacchino, Hamed Ekhtiari

Background and aims: COVID-19 has infected more than 13 million people worldwide and impacted the lives of many more, with a particularly devastating impact on vulnerable populations, including people with substance use disorders (SUDs). Quarantines, travel bans, regulatory changes, social distancing and 'lockdown' measures have affected drug and alcohol supply chains and subsequently their availability, price and use patterns, with possible downstream effects on presentations of SUDs and demand for treatment. Given the lack of multicentric epidemiologic studies, we conducted a rapid global survey within the International Society of Addiction Medicine (ISAM) network in order to understand the status of substance-use patterns during the current pandemic. Design: Cross-sectional survey. Setting: Worldwide. Participants: Starting on April 4th, 2020 during a 5-week period, the survey received 185 responses from 77 countries. Measurements: To assess addiction medicine professionals' perceived changes in drug and alcohol supply, price, use pattern and related complications during the COVID-19 pandemic. Findings: Participants reported (among who answered ''decreased'' or ''increased'', percentage of those who were in majority is reported in the parenthesis) a decrease in drug supply (69.0%), and at the same time an increase in price (95.3%) globally. With respect to changes in use patterns, an increase in alcohol (71.7%), cannabis (63.0%), prescription opioids (70.9%), and sedative/hypnotics (84.6%) use was reported while the use of amphetamines (59.7%), cocaine (67.5%), and opiates (58.2%) was reported to decrease overall. Conclusions: The global report on changes in the availability, use patterns and complications of alcohol and drugs during the COVID-19 pandemic should be considered in making new policies and in developing mitigating measures and guidelines during the current pandemic (and probable future ones) in order to minimize risks to SUDs. Key words: COVID-19, pandemic, alcohol, drug, substance use disorder, supply, price.

3: Take-Home Dosing Experiences among Persons Receiving Methadone Maintenance Treatment During COVID-19
more details view paper

Posted 02 Sep 2020

Take-Home Dosing Experiences among Persons Receiving Methadone Maintenance Treatment During COVID-19
1,053 downloads medRxiv addiction medicine

Mary C. Figgatt, Zach Salazar, Elizabeth Day, Louise Vincent, Nabarun Dasgupta

PurposeMethadone maintenance treatment is a life-saving treatment for people with opioid use disorders (OUD). The coronavirus pandemic (COVID-19) introduces many concerns surrounding access to opioid treatment. In March 2020, the Substance Abuse and Mental Health Services Administration (SAMHSA) issued guidance allowing the expansion of take-home methadone doses. We sought to describe changes to treatment experiences from the perspective of persons receiving methadone at outpatient treatment facilities for OUD. MethodsWe conducted an in-person survey among 104 persons receiving methadone from three clinics in central North Carolina in June and July 2020. Surveys collected information on demographic characteristics, methadone treatment history, and experiences with take-home methadone doses in the context of COVID-19 (i.e., before and since March 2020). ResultsBefore COVID-19, the clinic-level percent of participants receiving any amount of days supply of take-home doses at each clinic ranged from 56% to 82%, while it ranged from 78% to 100% since COVID-19. The clinic-level percent of participants receiving a take-homes days supply of a week or longer (i.e., [≥]6 days) since COVID-19 ranged from 11% to 56%. Among 87 participants who received take-homes since COVID-19, only four reported selling their take-home doses. ConclusionsOur study found variation in experiences of take-home dosing by clinic and little diversion of take-home doses. While SAMSHA guidance should allow expanded access to take-home doses, adoption of these guidelines may vary at the clinic level. The adoption of these policies should be explored further, particularly in the context of benefits to patients seeking OUD treatment. HighlightsO_LIMethadone take-home dosing of survey participants varied by clinic. C_LIO_LIDiversion of take-home doses was rare. C_LIO_LIImplementation of COVID-19 opioid treatment guidelines should be examined further. C_LI

4: Problem drinking before and during the COVID-19 crisis in US and UK adults: Evidence from two population-based longitudinal studies
more details view paper

Posted 28 Jun 2020

Problem drinking before and during the COVID-19 crisis in US and UK adults: Evidence from two population-based longitudinal studies
1,043 downloads medRxiv addiction medicine

Michael Daly, Eric Robinson

Background The impact of the COVID-19 crisis on potentially harmful alcohol consumption is unclear. Aims To test whether the prevalence of problem drinking has changed from before to during the COVID-19 crisis in the US and UK. Design/Setting We examined nationally representative longitudinal data on how problem drinking has changed from pre-pandemic levels among adults in the US (N=7,327; Understanding America Study) and UK (N=12,594; UK Household Longitudinal Study). Methods In the US, we examined rates of consuming alcohol [&ge;] 4 times in the past week at baseline (March, 2020) and across four waves of follow-up (April-May, 2020). In the UK we assessed the prevalence of consuming alcohol [&ge;] 4 times per week and weekly heavy episodic drinking using the AUDIT-C at baseline (2017-2019) and during the COVID-19 lockdown (April, 2020). We also tested whether there were specific groups at greater risk of increased problem drinking during the pandemic. Results Among US adults, there was a statistically significant increase in the percentage of participants reporting drinking alcohol [&ge;] 4 times a week which rose significantly from 11.7% to 17.9% (53% increase, p < .001) as the COVID-19 crisis developed in the US. Among UK adults, the percentage of participants reporting drinking [&ge;] 4 times a week increased significantly from 14.2% to 23% (62% increase, p < .001) and heavy episodic drinking at least weekly increased significantly from 9.7% to 16.6% (71% increase, p < .001) when compared to pre-COVID-19 lockdown levels. Trends were similar across population demographics, although those aged under 50 years and higher income groups displayed the largest increases. Conclusions The COVID-19 crisis has been associated with substantial increases in problematic drinking in both US and UK adults.

5: A Randomized Controlled Trial of a Digital Therapeutic Intervention for Smoking Cessation.
more details view paper

Posted 26 Jun 2020

A Randomized Controlled Trial of a Digital Therapeutic Intervention for Smoking Cessation.
984 downloads medRxiv addiction medicine

Jamie Webb, Sarrah Peerbux, Peter Smittenaar, Sarim Siddiqui, Yusuf Sherwani, Maroof Ahmed, Hannah MacRae, Hannah Puri, Sangita Bhalla, Azeem Majeed

Background and Aims: Tobacco smoking remains the leading cause of preventable death and disease worldwide. Digital interventions delivered through smartphones offer a promising alternative to traditional methods, but little is known about their effectiveness. Our aim was to determine the effectiveness of Quit Genius, a novel digital therapeutic intervention for smoking cessation. Design: Two-arm, single-blinded, parallel-group randomized controlled trial Setting: Referrals from primary care practices Participants: 556 Adult smokers (aged [&ge;]18 years), smoking at least five cigarettes a day for the past year. 530 were included for the final analysis. Intervention and comparator: Digital therapeutic intervention for smoking cessation consisting of a smartphone application delivering cognitive behavioral therapy content, one-to-one coaching, craving tools and tracking capabilities. The control intervention was Very Brief Advice along the Ask, Advise, Act model. All participants were offered nicotine replacement therapy for three months. A random half of each arm was assigned a carbon monoxide (CO) device for biochemical verification. Measurements: The primary outcome was self-reported seven-day point prevalence abstinence at four-weeks post quit date. Findings: 556 participants were randomized (treatment n=277, control n=279). The intention-to-treat analysis included 530 participants (n=265 in each arm; 11 excluded for randomization before trial registration, and 15 for protocol violations at baseline visit). At four weeks post-quit date, 45% of participants in the treatment arm had not smoked in the preceding seven days, compared to 29% in control (risk ratio 1.55 [1.23, 1.96], p = 0.0002; intention-to-treat, n=530). Self-reported seven-day abstinence agreed with CO measurement (CO <10 ppm) in 96% of cases (80/83) where CO readings were available. No harmful effects of the intervention were observed. Conclusions: The Quit Genius digital therapeutic intervention is a superior treatment in achieving smoking cessation four weeks post quit date compared to very brief advice.

6: Genetic Data Can Lead to Medical Discrimination: Opioid Use Disorder as a Cautionary Tale
more details view paper

Posted 14 Sep 2020

Genetic Data Can Lead to Medical Discrimination: Opioid Use Disorder as a Cautionary Tale
808 downloads medRxiv addiction medicine

Alexander S. Hatoum, Frank R. Wendt, Marco Galimberti, Renato Polimanti, Benjamin Neale, Henry R. Kranzler, Joel Gelernter, Howard J. Edenberg, Arpana Agrawal

Using genetics to predict the likelihood of future psychiatric disorders such as Opioid Use Disorder (OUD) poses scientific and ethical challenges. This report illustrates flaws in current machine learning (ML) approaches to such predictions using, as an example, a proposed genetic test for OUD derived from 16 candidate gene variants. In an independent sample of OUD cases and controls of European and African descent, results from five ML algorithms trained with purported "reward-system" candidate variants demonstrate that ML methods predict genomic ancestry rather than OUD. Further, sets of variants matched to the candidate SNPs by allele frequency produced similarly flawed predictions, questioning the plausibility of the selected candidate variants. We conclude that the genetic prediction of OUD (and by extension other highly polygenic psychiatric diseases) by ML has high potential to increase the likelihood of medical discrimination against population subgroups, with no benefit of accurate prediction for early intervention.

7: Reorganization of Substance Use Treatment and Harm Reduction Services during the COVID-19 Pandemic: A Global Survey
more details view paper

Posted 22 Sep 2020

Reorganization of Substance Use Treatment and Harm Reduction Services during the COVID-19 Pandemic: A Global Survey
755 downloads medRxiv addiction medicine

Seyed Ramin Radfar, Cornelis A J De Jong, Ali Farhoudian, Mohsen Ebrahimi, Parnian Rafei, Mehrnoosh Vahidi, Masud Yunesian, Christos Kouimtsidis, Shalini Arunogiri, Omid Massah, Abbas Deylamizadeh, Kathleen T Brady, Anja Busse, ISAM-PPIG Global Survey Consortium, Marc Potenza, Hamed Ekhtiari, Alexander Mario Baldacchino

Background: The COVID-19 pandemic has impacted people with substance use disorders (SUDs) worldwide, and healthcare systems have reorganized their services in response to the pandemic. Methods: One week after the announcement of the COVID-19 as a pandemic, in a global survey, 177 addiction medicine professionals described COVID-19-related health responses in their own 77 countries in terms of SUD treatment and harm reduction services. The health response is categorized around (1) managerial measures and systems, (2) logistics, (3) service providers, and (4) vulnerable groups. Results: Respondents from over 88% of countries reported that core medical and psychiatric care for SUDs had continued; however, only 56% of countries reported having had any business continuity plan, and 37.5% of countries reported shortages of methadone or buprenorphine supplies. Participants of 41% of countries reported partial discontinuation of harm-reduction services such as needle and syringe programs and condom distribution. 57% of overdose prevention interventions and 81% of outreach services also having been negatively impacted. Conclusions: Participants reported that SUD treatment and harm reduction services had been significantly impacted globally early during the COVID-19 pandemic. Based on our findings, we provide a series of recommendations to support countries to be prepared more efficiently for future waves or similar pandemics to 1) help policymakers generate business continuity plans, 2) maintain the use of evidence-based interventions for people with SUDs, 3) be prepared for adequate medication supplies, 4) integrate harm reduction programs with other treatment modalities and 5) have specific considerations for vulnerable groups such as immigrants and refugees.

8: Clinical and functional connectivity outcomes of 5-Hz repeated transcranial magnetic stimulation as an add-on treatment in cocaine use disorder: a double-blind randomized controlled trial.
more details view paper

Posted 19 Jul 2020

Clinical and functional connectivity outcomes of 5-Hz repeated transcranial magnetic stimulation as an add-on treatment in cocaine use disorder: a double-blind randomized controlled trial.
694 downloads medRxiv addiction medicine

Eduardo A. Garza-Villarreal, Ruth Alcala-Lozano, Sofia Fernandez-Lozano, Erik Morelos-Santana, Alan Dávalos, Viviana Villicaña, Sarael Alcauter, F. Xavier Castellanos, Jorge J. Gonzalez-Olvera

BACKGROUND: Cocaine use disorder (CUD) is a global condition lacking effective treatment. Repeated magnetic transcranial stimulation (rTMS) may reduce craving and frequency of cocaine use, but little is known about its efficacy and neural effects. METHODS: Using a double-blind placebo-controlled randomized clinical trial (RCT) [NCT02986438], we sought to elucidate short- and long-term clinical benefits of 5-Hz rTMS as an add-on to standard treatment in CUD patients and discern underlying functional connectivity effects using magnetic resonance imaging. Forty-four randomly assigned CUD patients completed the 2-week double-blind acute phase [Sham (n=20, 2f/18m) and Active (n=24, 4f/20m)], in which they received 2 daily sessions of rTMS (5,000 pulses) on the left dorsolateral prefrontal cortex. Subsequently, n=20 CUD patients continued to open-label maintenance (2 weekly sessions for up to 6 months). Measures were acquired at baseline, 2 weeks, 3 months and 6 months. RESULTS: Overall, 5-Hz rTMS plus standard treatment for 2 weeks significantly reduced craving and impulsivity in the Active group; decreased impulsivity correlated with improvements in functional connectivity in executive control and default mode networks. Clinical and functional connectivity effects were maintained for 3 months but they dissipated by 6 months. We did not observe reduction of positive cocaine urine tests, however, self-reported frequency and grams consumed for 6 months were reduced. CONCLUSIONS: With this RCT we show that 5-Hz rTMS has potential promise as an adjunctive treatment for CUD and merits further research.

9: Optimal Control Strategy Applied to Dynamic Model of Drug Abuse Incident for Reducing Its Adverse Effects
more details view paper

Posted 06 May 2020

Optimal Control Strategy Applied to Dynamic Model of Drug Abuse Incident for Reducing Its Adverse Effects
669 downloads medRxiv addiction medicine

Md. Haider Ali Biswas, Md. Azmir Ibne Islam

The present world is facing a devastating reality as drug abuse prevails in every corner of a society. The progress of a country is obstructed due to the excessive practice of taking drugs by the young generation. Like other countries, Bangladesh is also facing this dreadful situation. The multiple use of drug substances leads an individual to a sorrowful destination and for this reason, the natural behavior of human mind is disrupted. An addicted individual may regain his normal life by proper monitoring and treatment. The objective of this study is to analyze a mathematical model on the dynamics of drug abuse in the perspective of Bangladesh and reduce the harmful consequences with effective control policies using the idea of optimal control theory. The model has been solved analytically introducing a specific optimal goal. Numerical simulations have also been performed to review the behaviors of analytical findings. The analytical results have been verified with the numerical simulations. The analysis of this paper shows that it is possible to control drug addiction if there is less interaction among general people with the addicted individuals. Family based care, proper medical treatment, awareness and educational programs can be the most effective ways to reduce the adverse effects of drug addiction in a shortest possible time.

10: Associations between inhibitory control, stress, and alcohol (mis)use during the first wave of the COVID-19 pandemic in the UK: a national cross-sectional study utilising data from four birth cohorts
more details view paper

Posted 25 Sep 2020

Associations between inhibitory control, stress, and alcohol (mis)use during the first wave of the COVID-19 pandemic in the UK: a national cross-sectional study utilising data from four birth cohorts
649 downloads medRxiv addiction medicine

James M Clay, Lorenzo D Stafford, Matthew O Parker

Aims. To investigate: (1) alcohol use during the pandemic in the UK; and (2) the extent to which poor inhibitory control and/or stress were associated with any change in alcohol use or hazardous drinking. Design. Cross-sectional online survey administered between 2 and 31 May 2020. Setting. UK. Participants. 13,453 respondents aged 19 - 62 years comprising participants of four nationally representative birth cohorts (19, 30, 50 and 62-years old). Measurements. Change in alcohol use and risk of alcohol-related harm due to hazardous drinking and change in stress since the start of the Coronavirus outbreak; inhibitory control (impatience and risk-taking); and sociodemographic characteristics, including diagnosed or suspected COVID-19, and key worker status. Findings. Most respondents reported consuming/feeling the same amount or less alcohol/stress. However, a significant minority, particularly among thirty- (29.08%) and fifty-year-olds (26.67%), reported drinking more, and between 32.23% and 45.02% of respondents reported feeling more stressed depending on cohort. Being female was associated with an increased likelihood of reporting heightened stress (OR19 = 1.54, 95% CI 1.08 to 2.20; OR30 = 1.93, 95% CI 1.39 to 2.70; OR50 = 1.62, 95% CI 1.37 to 1.92; OR62 = 2.03, 95% CI 1.66 to 2.48). Stress was associated with hazardous drinking among 30-year-olds (OR = 3.77, 95% CI 1.15 to 12.28). Impatience was associated with both increased alcohol use (1.14, 95% CI 1.06, 1.24) and hazardous drinking (1.20, 95% CI 1.05, 1.38) among 19-year-olds. Risk-taking was associated with hazardous drinking for 30-year-olds (OR = 1.18, 95% CI 1.05, 1.32). Conclusions. These data highlight concerns about the UK government's stance on the "essential" nature of off-premises alcohol sales during the lockdown, particularly from a public health perspective, when considering those at risk of alcohol misuse and alcohol-related harm.

11: Polygenic Risk Scores for Alcohol Involvement Relate to Brain Structure in Substance-Naive Children: Results from the ABCD Study
more details view paper

Posted 28 Jul 2020

Polygenic Risk Scores for Alcohol Involvement Relate to Brain Structure in Substance-Naive Children: Results from the ABCD Study
628 downloads medRxiv addiction medicine

Alexander S. Hatoum, Emma C. Johnson, David AA Baranger, Sarah E. Paul, Arpana Agrawal, Ryan Bogdan

In substance naive children (n=3,013), polygenic risk score (PRS) for problematic alcohol use was associated with lower volume of the frontal pole and greater cortical thickness of the supramarginal gyrus. Several other areas showed nominal significance. These associations suggest that genetic liability to alcohol involvement may manifest as variability in brain structure prior to consumption of the first alcoholic drink and alter brain morphometry during the start of adolescence.

12: Machine Learning Applied to Clinical Laboratory Data Predicts Patient-Specific, Near-Term Relapse in Patients in Medication for Opioid Use Disorder Treatment
more details view paper

Posted 14 Aug 2020

Machine Learning Applied to Clinical Laboratory Data Predicts Patient-Specific, Near-Term Relapse in Patients in Medication for Opioid Use Disorder Treatment
594 downloads medRxiv addiction medicine

Paul Pyzowski, Barbara Herbert, Wasim Q. Malik

We have developed a data-driven, algorithmic method for identifying patients in an outpatient buprenorphine program at high risk for relapse in the following seven days. This method uses data already available in clinical laboratory data, can be made available in a timely matter, and is easily understandable and actionable by clinicians. Use of this method could significantly reduce the rate of relapse in addiction treatment programs by targeting interventions at those patients most at risk for near term relapse.

13: Genetic Liability to Cannabis Use Disorder and COVID-19 Hospitalization
more details view paper

Posted 18 Nov 2020

Genetic Liability to Cannabis Use Disorder and COVID-19 Hospitalization
570 downloads medRxiv addiction medicine

Alexander S. Hatoum, Claire L Morrison, Evan A. Winiger, Emma C. Johnson, Arpana Agrawal, Ryan Bogdan

Behavioral and life style factors plausibly play a role in likelihood of being hospitalized for COVID-19. Genetic vulnerability to hospitalization after SARS-CoV2 infection may partially relate to comorbid behavioral risk factors, especially the use of combustible psychoactive substances. Paralleling the COVID-19 crisis has been increasingly permissive laws for recreational cannabis use. Cannabis Use Disorder (CUD) is a psychiatric disorder that is heritable and genetically correlated with respiratory disease, independent of tobacco smoking. By leveraging genome-wide association summary statistics of CUD and COVID-19, we find that at least 1/3rd of the genetic vulnerability to COVID-19 overlaps with genomic liability to CUD (rg=.34, p=0.0003). Genetic causality as a potential mechanism of risk could not be excluded. The association between CUD and COVID-19 remained when accounting for genetics of trying marijuana, tobacco smoking (ever smoking regularly, cigarettes per day, smoking cessation, age of smoking initiation), BMI, fasting glucose, forced expiration volume, education attainment, and Townsend deprivation index. Heavy problematic cannabis use may increase chances of hospitalization due to COVID-19 respiratory complications. Curbing excessive cannabis use may be an essential strategy in COVID-19 mitigation.

14: Predicting Alcohol Dependence from Multi-Site Brain Structural Measures
more details view paper

Posted 23 Jan 2020

Predicting Alcohol Dependence from Multi-Site Brain Structural Measures
544 downloads medRxiv addiction medicine

Sage Hahn, Scott Mackey, Janna Cousijn, John J. Foxe, Robert Hester, Kent Hutchinson, Ozlem Korucuoglu, Edythe London, Valentina Lorenzetti, Maartje Luijten, Reza Momenan, Catherine Orr, Martin Paulus, Lianne Schmaal, Rajita Sinha, Zsuzsika Sjoerds, Dan Stein, Elliot Stein, Ruth J. van Holst, Dick Veltman, Reinout W Wiers, Murat Yucel, Paul M. Thompson, Patricia Conrod, Nicholas Allgaier, Hugh Garavan

BackgroundThe search for neuroimaging biomarkers of alcohol use disorder (AUD) has primarily been restricted to significance testing in small datasets of low diversity. To identify neurobiological markers beyond individual differences, it may be useful to develop classification models for AUD. The ever-increasing quantity of neuroimaging data demands methods that are robust to the complexities of multi-site designs and are generalizable to data from new scanners. MethodsThis study represents a mega-analysis of previously published datasets from 2,034 AUD and comparison participants spanning 27 sites, coordinated by the ENIGMA Addiction Working Group. Data were grouped into a training set including 1,652 participants (692 AUD, 24 sites), and test set with 382 participants (146 AUD, 3 sites). A battery of machine learning classifiers was evaluated using repeated random cross-validation (CV) and leave-site-out CV. Area under the receiver operating characteristic curve (AUC) was our base metric of performance. ResultsMulti-objective evolutionary search was conducted to identify sparse, generalizable, and high performing subsets of brain measurements. Cortical thickness in the left superior frontal gyrus and right lateral orbitofrontal cortex, cortical surface area in the right transverse temporal gyrus, and left putamen volume, appeared most frequently across searches. Restricting a regularized logistic regression model to these four features yielded a test-set AUC of .768. ConclusionsDeveloping classification models on multi-site data with varied underlying class distributions poses unique challenges. Supplementing datasets with controls from new sites and performing feature selection increases generalizability. Four features identified by evolutionary search may serve as specific biomarkers for individuals with current AUD.

15: Increasing Heroin, Cocaine, and Buprenorphine Arrests Reported to the Maine Diversion Alert Program
more details view paper

Posted 09 Aug 2019

Increasing Heroin, Cocaine, and Buprenorphine Arrests Reported to the Maine Diversion Alert Program
529 downloads medRxiv addiction medicine

Kevin J Simpson, Matthew T Moran, Kenneth L McCall, John Herbert, Michelle Foster, Olapeju M Simoyan, Dipam T Shah, Clare Desrosiers, Stephanie D. Nichols, Brian J. Piper

BackgroundThe opioid overdose crisis is especially pronounced in Maine. The Diversion Alert Program (DAP) was developed to combat illicit drug use and prescription drug diversion by facilitating communication between law enforcement and healthcare providers with the goal of limiting drug-related harms and criminal behaviors. Our objectives in this report were to analyze 2014-2017 DAP for: 1) trends in drug arrests and, 2) differences in arrests by offense, demographics (sex and age) and by region. MethodsDrug charges (N = 8,193, 31.3% female, age = 33.1 {+/-} 9.9) reported to the DAP were examined by year, demographics, and location. ResultsThe most common substances of the 10,064 unique arrests reported were heroin (N = 2,203, 21.9%), crack/cocaine (N = 945, 16.8%), buprenorphine (N = 812, 8.1%), and oxycodone (N = 747, 7.4%). While the overall number of arrests reported to the DAP declined in 2017, the proportion of arrests involving opioids (heroin, buprenorphine, or fentanyl) and stimulants (cocaine/crack cocaine, or methamphetamine), increased (p < .05). Women had significantly increased involvement in arrests involving sedatives and miscellaneous pharmaceuticals (e.g. gabapentin) while men had an elevation in stimulant arrests. Heroin accounted for a lower percentage of arrests among individuals age > 60 (6.6%) relative to young-adults (18-29, 22.3%, p < .0001). Older-adults had significantly more arrests than younger-adults for oxycodone, hydrocodone, and marijuana. ConclusionHeroin had the most arrests from 2014-2017. Buprenorphine, fentanyl and crack/cocaine arrests increased appreciably suggesting that improved treatment is needed to prevent further nonmedical use and overdoses. The Diversion Alert Program provided a unique data source for research, a harm-reduction tool for health care providers, and an informational resource for law enforcement.

16: Convergent cross-sectional and longitudinal evidence for gaming-cue specific posterior parietal dysregulations in early stages of Internet Gaming Disorder
more details view paper

Posted 24 Jan 2020

Convergent cross-sectional and longitudinal evidence for gaming-cue specific posterior parietal dysregulations in early stages of Internet Gaming Disorder
528 downloads medRxiv addiction medicine

Fangwen Yu, Rayna Sariyska, Bernd Lachmann, Qianqian Wang, Martin Reuter, Bernd Weber, Peter Trautner, Shuxia Yao, Christian Montag, Benjamin Becker

Exaggerated reactivity to drug-cues and emotional dysregulations represent key symptoms of early stages of substance use disorders. The diagnostic criteria for (Internet) Gaming Disorder strongly resemble symptoms for substance-related addictions. However, previous cross-sections studies revealed inconsistent results with respect to neural cue reactivity and emotional dysregulations in these populations. To this end the present fMRI study applied a combined cross-sectional and prospective longitudinal design in excessive online gamers (n=37) and gaming-naive controls (n=67). To separate gaming-associated changes from predisposing factors, gaming-naive subjects were randomly assigned to 6 weeks of daily Internet gaming or a non-gaming condition. At baseline and after the training subjects underwent an fMRI paradigm presenting gaming-related cues and non-gaming related emotional stimuli. Cross-sectional comparisons revealed gaming-cue specific enhanced valence attribution and neural reactivity in a parietal network, including the posterior cingulate/precuneus in excessive gamers as compared to gaming naive-controls. Prospective analysis revealed that six weeks of gaming elevated valence ratings as well as neural cue-reactivity in a similar parietal network, specifically the posterior cingulate/precuneus in previously gaming-naive controls. Together, the prospective longitudinal design did not reveal supporting evidence for altered emotional processing of non-gaming associated stimuli in excessive gamers while convergent evidence for increased emotional and neural reactivity to gaming-associated stimuli was observed. Findings suggest that exaggerated neural reactivity in posterior parietal regions engaged in self-referential processing already occur during early stages of regular gaming probably promoting continued engagement in gaming behavior.

17: Rise and Regional Disparities in Buprenorphine Utilization in the United States
more details view paper

Posted 09 Sep 2019

Rise and Regional Disparities in Buprenorphine Utilization in the United States
519 downloads medRxiv addiction medicine

Amir Azar R. Pashmineh, Alexandra Cruz-Mullane, Jaclyn C. Podd, Warren S. Lam, Suhail H. Kaleem, Laura B. Lockard, Mark R. Mandel, Daniel Y. Chung, Corey S. Davis, Stephanie D. Nichols, Kenneth L McCall, Brian J. Piper

AimsBuprenorphine is an opioid partial-agonist used to treat Opioid Use Disorders (OUD). While several state and federal policy changes have attempted to increase buprenorphine availability, access remains well below optimal levels. This study characterized how buprenorphine utilization in the United States has changed over time and whether there are regional disparities in distribution. MeasurementsBuprenorphine weights distributed from 2007 to 2017 were obtained from the Drug Enforcement Administration. Data was expressed as the percent change and as the mg per person in each state. Separately, the formulations for prescriptions covered by Medicaid (2008 to 2018) were examined. FindingsBuprenorphine distributed to pharmacies increased about seven-fold (476.8 to 3,179.9 kg) while the quantities distributed to hospitals grew five-fold (18.6 to 97.6 kg) nationally from 2007 to 2017. Buprenorphine distribution per person was almost 20-fold higher in Vermont (40.4 mg/person) relative to South Dakota (2.1 mg/person). There was a strong association between the number of waivered physicians per 100K population and distribution per state (r(49) = +0.76, p < .0005). The buprenorphine/naloxone sublingual film (Suboxone) was the predominant formulation (92.6% of 0.31 million Medicaid prescriptions) in 2008 but this accounted for less than three-fifths (57.3% of 6.56 million prescriptions) in 2018. ConclusionsAlthough buprenorphine availability has substantially increased over the last decade, distribution was very non-homogenous across the US.

18: A meta-analysis of cocaine use disorder treatment effectiveness
more details view paper

Posted 11 Jun 2020

A meta-analysis of cocaine use disorder treatment effectiveness
518 downloads medRxiv addiction medicine

Brandon Stephen Bentzley, Summer S Han, Sherman C Stein, Sophie Neuner, Keith Humphreys, Kyle M Kampman, Casey Harrison Halpern

Background: In both the U.S. and U.K., after a period of decline, prevalence of cocaine use has been increasing since 2012 and is now the second leading cause of overdose death from an illicit drug. However, psychosocial treatments for cocaine use disorders are limited, and no pharmacotherapy is approved by regulatory bodies in the U.S. or Europe. We performed a comprehensive meta-analysis to assess treatments impacts on cocaine use. Methods: We performed a meta-analysis of clinical trials that included the word "cocaine" in the title and were published between 31/12/1995 and 31/12/2017. All studies of outpatient adults with active cocaine use and reporting urinalysis results were included. Treatment approaches were clustered into 11 categories. Missing data were imputed using multiple imputation by chained equations. We calculated intention-to-treat log-odds ratios (OR) for the change in proportion of patients testing negative for cocaine at the end of each study and performed multivariate mixed-effects meta-regression. This study was prospectively registered on covidence.org on 31/12/2015, study 8731. Findings: One hundred fifty-seven studies with 15,842 participants were included. Only contingency management was significantly associated with increased odds of testing negative for cocaine (OR of 2.13, 95% CI 1.62-2.80) and remained significant after all sensitivity analyses. Interpretation: This meta-analysis is unique in its broad inclusivity of treatment types and trial designs over a two-decade period of investigation. Our results converge with focused meta-analyses on treatments for cocaine use disorders; thus, research efforts and policy changes that expanded implementation of contingency management programs are expected to reduce cocaine use in active users and the associated individual, community, and societal burdens associated.

19: Peripheral Biomarkers of Tobacco-Use Disorder: A Systematic Review
more details view paper

Posted 14 Aug 2019

Peripheral Biomarkers of Tobacco-Use Disorder: A Systematic Review
500 downloads medRxiv addiction medicine

Dwight F. Newton

IntroductionTobacco use disorder (TUD) is a major worldwide healthcare burden resulting in 7 million deaths annually. TUD has few approved cessation aids, all of which are associated a high rate of relapse within one year. Biomarkers of TUD severity, treatment response, and risk of relapse have high potential clinical utility to identify ideal responders and guide additional treatment resources. MethodsA MEDLINE search was performed using the terms biomarkers, dihydroxyacetone phosphate, bilirubin, inositol, cotinine, adrenocorticotropic hormone, cortisol, pituitary-adrenal system, homovanillic acid, dopamine, pro-opiomelanocortin, lipids, lipid metabolism all cross-referenced with tobacco-use disorder. ResultsThe search yielded 424 results, of which 57 met inclusion criteria. The most commonly studied biomarkers were those related to nicotine metabolism, the hypothalamic-pituitary-adrenal (HPA) axis, and cardiovascular (CVD) risk. Nicotine metabolism was most associated with severity of dependence and treatment response, where as HPA axis and CVD markers showed less robust associations with dependence and relapse risk. ConclusionsNicotine-metabolite ratio, cortisol, and atherogenicity markers appear to be the most promising lead biomarkers for further investigation, though the body of literature is still preliminary. Longitudinal, repeated-measures studies are required to determine the directionality of the observed associations and determine true predictive power of these biomarkers. Future studies should also endeavour to study populations with comorbid psychiatric disorders to determine differences in utility of certain biomarkers.

20: The Concurrent Initiation of Medications Is Associated with Discontinuation of Buprenorphine Treatment for Opioid Use Disorder
more details view paper

Posted 18 Jan 2020

The Concurrent Initiation of Medications Is Associated with Discontinuation of Buprenorphine Treatment for Opioid Use Disorder
495 downloads medRxiv addiction medicine

Pengyue Zhang, Chien-Wei Chiang, Sara Quinney, Macarius Donneyong, Bo Lu, Lei Frank Huang, Feixiong Cheng

IntroductionRetention in buprenorphine treatment for opioid use disorder (OUD) yields better opioid abstinence and reduces all-cause mortality for patients with OUD. Despite significant efforts have been made to expand the availability and use of buprenorphine in the United States, its retention rates remain on a low level. The current study examines discontinuation of buprenorphine with respect to concurrent initiation of other medications using real-world evidence. MethodsCase-crossover study was conducted to examine discontinuation of buprenorphine using a large-scale longitudinal health dataset including 148,306 commercially-insured individuals initiated on medications for opioid use disorder (MOUD). Odds ratios and Bonferroni adjusted p-values were calculated for medications and therapeutic classes of medications. ResultsClonidine was associated with increased discontinuation risk of buprenorphine both using the buprenorphine dataset alone (OR = 1.583 and adjusted p-value = 1.22 x 10-6) and using naltrexone as a comparison drug (OR = 2.706 and adjusted p-value = 4.11 x 10-5). Opioid medications (oxycodone, morphine and fentanyl) and methocarbamol were associated with increased discontinuation risk of buprenorphine using the buprenorphine dataset alone (adjusted p-value < 0.05), but not significant using naltrexone as a comparison drug. 6 drug therapeutic classes were associated with increased discontinuation risk of buprenorphine both using the buprenorphine dataset alone and using naltrexone as a comparison drug (adjusted p-value < 0.05). ConclusionConcurrent initiation of medications is associated with increased discontinuation risk of buprenorphine. Opioid medications are prescribed among patients on MOUD and associated with increased discontinuation risk of buprenorphine. Analgesics is associated with increased discontinuation risk of buprenorphine for patients without previous exposure of pain medications.

Previous page 1 2 3 4 Next page

PanLingua

Sign up for the Rxivist weekly newsletter! (Click here for more details.)


News